ACC.24 - Brian Bergmark discusses the results of the BRIDGE-TIMI 73a trial in patients with either moderate hypertriglyceridemia and elevated CV risk or with severe hypertriglyceridemia. “Olezarsen reduced triglycerides levels to an extent that is greater than currently available drugs”.